Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.

BACKGROUND Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) are rare and aggressive thyroid cancers with limited published data comparing their outcomes or regarding their subtypes. The aim of this study was to describe clinicopathological features and compare clinical outcomes of patients with FTC and HCC based on the 2017 World Health Organization definition and extent of vascular invasion (VI). METHODS We retrospectively studied 190 patients with HCC and FTC primarily treated with surgery at Memorial Sloan Kettering Cancer Center between 1986 and 2015. Patients were classified as minimally invasive (MI), encapsulated angioinvasive with focal VI (EA-FVI), encapsulated angioinvasive with extensive VI (EA-EVI) and as widely invasive (WI). To compare clinical outcomes, patients were grouped as follows: group 1= FTC-MI and FTC EA-FVI, group 2= FTC EA-EVI and FTC-WI, group 3= HCC-MI and HCC EA-FVI, group 4= HCC EA-EVI and HCC-WI. Outcomes of interest were overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), locoregional recurrence-free survival (LRRFS), and distant recurrence-free survival (DRFS). Outcomes were determined using the Kaplan-Meier method and compared with log-rank test. RESULTS Patients with HCC (n=111) were more likely to be older than 55 years old (59% vs 27%, p<0.001) with a tendency to present with more extensive VI (33% vs 19%, p=0.07) compared with FTC (n=79). Comparing groups 1,2,3, and 4, group 4 patients were more likely to recur (DFS 98%, 93%, 98% vs 73%, respectively, p=0.0069). There was no statistically significant difference in OS, DSS LRRFS or DRFS. Stratified by extent of VI (no, focal and extensive VI), patients with extensive VI were more likely to recur (RFS 100%, 95%, 77%, p=0.0025) and had poorer distant control (DRFS: 100%, 95%, 80%, p=0.022), compared with patients absent or focal VI. CONCLUSIONS Accurate assessment of the extent of VI and tumor phenotype (Follicular vs Hurthle) are essential in identifying patients at higher risk of recurrence.  .

[1]  H. Hundeshagen,et al.  Risk Factors in Follicular Thyroid Carcinomas: A Retrospective Follow-up Study Covering a 14-Year Period with Emphasis on Morphological Findings , 1986, The American journal of surgical pathology.

[2]  L. Souhami,et al.  Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers , 2010, Journal of Neuro-Oncology.

[3]  T. Uruno,et al.  Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[4]  N. Socci,et al.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. , 2013, The Journal of clinical endocrinology and metabolism.

[5]  RiveraMichael,et al.  Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. , 2015 .

[6]  I. Ganly,et al.  Short Review: Genomic Alterations in Hürthle Cell Carcinoma. , 2019, Thyroid : official journal of the American Thyroid Association.

[7]  O. Clark,et al.  Hürthle cell carcinoma , 2001, Current treatment options in oncology.

[8]  E. Kaplan,et al.  Follicular thyroid cancer incidence patterns in the United States, 1980-2009. , 2013, Thyroid : official journal of the American Thyroid Association.

[9]  J. Shah,et al.  Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland , 2006, Cancer.

[10]  S. Pilotti,et al.  Extensive vascular invasion is a marker of risk of relapse in encapsulated non‐Hürthle cell follicular carcinoma of the thyroid gland: a clinicopathological study of 18 consecutive cases from a single institution with a 11‐year median follow‐up , 2004, Histopathology.

[11]  S. Asa,et al.  Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation , 2011, Modern Pathology.

[12]  N. Ordóñez,et al.  Prognostic factors in patients with Hürthle cell neoplasms of the thyroid , 2003, Cancer.

[13]  S. Baxi,et al.  Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer , 2017, Cancer.

[14]  N. Bhattacharyya.  Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. , 2003, Archives of otolaryngology--head & neck surgery.